Iterum Therapeutics plc (ITRMF) Net Income towards Common Stockholders (2017 - 2025)

Iterum Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$9.0 million for Q3 2025.

• In Q3 2025, Net Income towards Common Stockholders fell 47.34% year-over-year to -$9.0 million; the TTM figure through Sep 2025 stood at -$27.0 million (up 11.76% YoY), while the FY2024 annual figure was -$24.8 million, up 35.44% from the prior year.
• Net Income towards Common Stockholders for Q3 2025 stood at -$9.0 million, down from -$6.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $7.8 million in Q2 2021, with the low at -$98.9 million in Q1 2021.
• The 5-year median for Net Income towards Common Stockholders is -$6.5 million (2025), against an average of -$11.6 million.
• The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders jumped 162.28% in 2021, then tumbled 878.11% in 2022.
• Iterum Therapeutics' Net Income towards Common Stockholders stood at -$4.2 million in 2021, then decreased by 21.71% to -$5.1 million in 2022, then plunged by 142.87% to -$12.4 million in 2023, then jumped by 46.76% to -$6.6 million in 2024, then tumbled by 36.42% to -$9.0 million in 2025.
• Business Quant data shows ITRMF's Net Income towards Common Stockholders at -$9.0 million in Q3 2025, -$6.5 million in Q2 2025, and -$4.9 million in Q1 2025.